Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.
Ryo Morimoto is a Research Fellow and Group Leader at the Department of Molecular Biology, Umeå University, affiliated with Molecular Infection Medicine Sweden (MIMS). He leads studies on the evolutionary foundations of adaptive immunity and host genome editing mechanisms. MD (2011) and PhD (2017) from University of Tokyo Postdoctoral work at Max Planck Institute for Immunobiology & Epigenetics (2017-2024) Project Leader (2022) and Group Leader (2024) at MIMS His research explores antigen receptor diversification in jawless vertebrates, evolutionary emergence of lymphopoietic systems, and self-tolerance mechanisms. Using non-conventional models, his lab integrates in vitro biochemistry, single-cell omics, and computational genomics to address genome integrity challenges in adaptive immunity. The lab's recent publications highlight evolutionary insights into immune system development and its implications for human immunity. Research focuses on conserved enzyme families mediating genome editing and their biotechnological applications. Ryo Morimoto's team emphasizes multicultural collaboration, interdisciplinary training, and skill development for early-career scientists. The lab maintains partnerships with Umeå Centre for Microbial Research (UCMR) and employs in vivo techniques alongside molecular and computational approaches.
Kristin Bernard, Ph.D. (University of Delaware, 2013), is an Associate Professor of Clinical Psychology at Stony Brook University’s Department of Psychology. Her research focuses on the neurobiological consequences of early adversity, parent-child relationships, and the efficacy of early parenting interventions such as Attachment and Biobehavioral Catch-up (ABC). She collaborates with Power of Two, a NYC-based nonprofit, and leads the Developmental Stress and Prevention Lab. Current grants include studies on epigenomics, maternal attachment representation, and community-based ABC interventions. Dr. Bernard’s work bridges clinical and developmental psychology, emphasizing prevention science and translational research. Education: Ph.D. in Clinical Psychology, University of Delaware, 2013. Research Interests: Child maltreatment, neurobiological impacts of early adversity, parenting interventions, psychobiology of attachment, and intervention efficacy. Her lab investigates mechanisms linking caregiving quality to child outcomes, including cortisol regulation, brain development, and behavioral compliance. Lab & Partnerships: Directs the Developmental Stress and Prevention Lab, focusing on high-risk populations. Collaborations include Power of Two for ABC implementation and NYC agencies like the Administration for Children’s Services. Current projects explore neighborhood influences on parenting (Geography of Parenting Study) and neural correlates of parenting behavior (SNAP study). Grants & Funding: Principal Investigator on NIH-funded projects (R03 HD099372, R01 MH119310) and co-PI on Stony Brook’s seed grants. Projects examine accelerated aging biomarkers and intervention effectiveness in community settings. Publications: Over 50 peer-reviewed articles and a co-authored book on ABC interventions. High-impact journals include Psychoneuroendocrinology , Development and Psychopathology , and Child Development .
Jörg Bohlmann is a Professor in the Department of Forest and Conservation Sciences at the University of British Columbia , affiliated with the Michael Smith Laboratories, Botany Department (Faculty of Science), and Wine Research Centre. His research spans genomics, biochemistry, and chemical ecology of plant specialized metabolism, focusing on terpenoids and phenolics for applications in forest health and bioproducts. Research Streams : Plant defense against insects/pathogens, metabolic engineering of bioproducts, forest genomics, and molecular evolution of terpenoid pathways. Collaborations : National and international partnerships with academia, government, and biotech industries. Recent Publications highlight genomic insights into Western Redcedar (2023), including its low genetic diversity and adaptation mechanisms despite self-fertilization. Earlier work (2001–2022) covers conifer defense systems, Arabidopsis terpenoid pathways, cannabis flavor genetics, and mass spectrometry infrastructure. Scientific Awards include: NSERC E.W.R. Steacie Fellow (2015), Fellow of the Royal Society of Canada (2015), Feodor Lynen Postdoctoral Fellowship (1995–1998), and Distinguished University Scholar (UBC). Funding Sources : NSERC (Discovery/Strategic grants), CFI, Genome Canada/BC, provincial/federal agencies. Labs & Facilities : Michael Smith Laboratories (UBC), National Centre of Excellence, Forest Sciences Centre, and a dedicated mass spectrometry lab for metabolite analysis.
Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.
Michael Yeager, PhD, serves as an Associate Clinical Professor in the School of Medicine at the University of Colorado Denver, focusing on cardiopulmonary pathophysiology with emphasis on pulmonary hypertension and heart failure mechanisms. He completed his PhD at the University of Colorado Health Sciences Center in 2002, establishing foundational expertise in vascular biology. His research program investigates immunological and molecular drivers of pulmonary vascular disease, particularly the roles of autoantibodies, fibrocytes, and inflammatory cascades in disease progression. Analysis of his 14 publications (2012-2015) reveals consistent exploration of biomarker discovery, vascular remodeling, and immune dysregulation across pediatric and adult pulmonary hypertension. Key methodological approaches include proteomics, animal modeling, and molecular interrogation of cellular stress responses, with significant translational implications for personalized therapeutic strategies. Professional recognitions include: Outstanding Faculty award from Tau Beta Pi (2019) Chancellor's Teaching Recognition Award from the University of Colorado (2016) Dr. Yeager maintains active clinical research collaborations at Children's Hospital Colorado while mentoring within the medical school curriculum. His work bridges basic science discovery with clinical application through ongoing investigations into endothelial dysfunction and inflammatory mediators. Affiliated with the Department of Medicine, he contributes to pulmonary vascular research initiatives and participates in professional societies including the American Thoracic Society, American Heart Association, and T21 Research Society.
Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.
Thomas R Overton serves as Department Chair and Professor of Dairy Nutrition and Management in the Department of Animal Science at Cornell University's College of Agriculture and Life Sciences (CALS). He also directs PRO-DAIRY, an extension program focused on enhancing dairy farm profitability and efficiency in New York through research-based strategies for transition cow management. Education: Doctorate, University of Illinois, 1998 Master of Science, University of Illinois, 1994 Bachelor of Science, Cornell University, 1991 Dr. Overton's research centers on the transition period (late pregnancy to early lactation) in dairy cows—the most critical phase for health and productivity. His work integrates nutritional physiology with practical farm applications, targeting hypocalcemia management, protein supplementation strategies, inflammation control, and biomarker validation for metabolic health. This research directly informs his extension efforts through PRO-DAIRY, which delivers actionable knowledge to dairy producers and industry professionals. Analysis of his 15 most recent publications (2022-2024) reveals consistent emphasis on transition cow nutrition, with growing focus on metabolic analytics, precision feeding, and real-world herd management. His work bridges controlled studies at Cornell's Ruminant Center with observational research on commercial New York dairy farms. Scientific Awards: 2024 Nutrition Professionals Applied Dairy Research Award (American Dairy Science Association) 2010 CALS Extension/Outreach Team Award (PRO-DAIRY) 2007 Foundation Scholar Award (American Dairy Science Association) 2007 CALS Extension/Outreach Team Award Dr. Overton advises undergraduate and graduate students in Animal Science while leading PRO-DAIRY's extension initiatives. His program secures industry partnerships and grants focused on improving dairy farm sustainability through nutritional science. The July 2025 'Farm of the Future' showcase at Cornell's Ruminant Center exemplifies his commitment to translating research into practical innovation. He operates within Cornell's PRO-DAIRY program and the Cornell University Ruminant Center—a living laboratory for dairy technology testing—collaborating closely with industry stakeholders to address emerging challenges in dairy production.
Katherine Reece Thomas is a Global Associate Professor of Law at the Notre Dame London Law Programme and holds a primary affiliation as Associate Professor of Law at The City Law School, City St George's, University London. She specializes in public international law, company law, and the law of state immunity. Her teaching portfolio includes international law of the sea, contract law, and corporate law. She holds a BA(Hons) in History from McGill University, a BA(Hons) in Jurisprudence from the University of Oxford, and an LLM in International Law from the University of Cambridge. She is a retired member of the New York State Bar and a non-practising solicitor in England and Wales. Her research focuses on state immunity doctrines, international law domestication, and shareholders' agreements. Dr. Thomas served as Programme Director for City's LLM programmes from 2017–2022. Her publications include a monograph on the Commercial Activity Exception to State Immunity (Edward Elgar, 2024) and the upcoming sixth edition of The Law and Practice of Shareholders' Agreements (co-authored with Christopher Ryan). She also contributes to scholarly discussions on transnational legal frameworks and corporate governance structures.
Cecilie Schou Andreassen is a Professor at the Department of Clinical Psychology, University of Bergen . She specializes in behavioral addictions , including workaholism, social media addiction, and substance use interactions. Email: cecilie.andreassen@uib.no Visitor Address: Alrek Health Cluster, Årstadveien 17, 5009 Bergen Research Focus: Andreassen's work examines the psychosocial antecedents of addictive behaviors, with emphasis on personality traits , workplace dynamics , and digital platform interactions . Her research spans cross-cultural validation studies and longitudinal health outcomes related to technology and substance misuse. Article Trends (2017-2022): Analyzing 15 recent publications reveals a consistent focus on addiction scale validation , social media epidemiology , and workaholism's health impacts . Key themes include measurement invariance , digital-chemical addiction comorbidity , and psychological withdrawal mechanisms . Scientific Contributions: Co-developer of Bergen Work Addiction Scale Creator of Bergen-Yale Sex Addiction Scale Leadership in behavioral addiction epidemiology Recipient of Norwegian Research Council grants Advising & Collaborations: While no direct advisees are listed, Andreassen collaborates extensively with international researchers in work psychology , social media studies , and public health . Her work involves partnerships with Nottingham Trent University , Yale University , and National Competence Service for Sleep Disorders . Labs & Teams: Affiliated with the Department of Clinical Psychology and previously with the Department of Social Psychology at University of Bergen, she contributes to national health registry studies and cross-occupational research on addiction patterns.
Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.
Anirban Paul is an Associate Professor in the Department of Neuroscience and Experimental Therapeutics at Pennsylvania State University, affiliated with the Penn State Neuroscience Institute. His research focuses on cellular and molecular mechanisms of GABAergic inhibitory circuits, with particular emphasis on interneuron biology and its implications in neurological disorders. Dr. Paul's research spans multiple neuroscience domains, with primary focus on GABAergic inhibitory circuits and interneuron biology. His work investigates how specific neuron subtypes, particularly Chandelier cells and cortical interneurons, contribute to brain function and dysfunction. He has made significant contributions to understanding the role of these cells in schizophrenia, Alzheimer's disease, and other neurological conditions. His research integrates molecular, cellular, and systems-level approaches to uncover fundamental mechanisms of neural circuit assembly, plasticity, and function. Key areas include RNA regulation in neuronal development, transcriptomic subtypes of inhibitory neurons, and cell-type specific vulnerabilities in neurodegenerative diseases. His research portfolio demonstrates consistent productivity with publications spanning from 2003 to 2025, showing an evolving focus from basic molecular neuroscience to translational research in neurological disorders. Recent work emphasizes single-cell analysis techniques and the role of specific interneuron populations in disease mechanisms, particularly in schizophrenia and Alzheimer's disease. His publications appear in high-impact neuroscience journals including Neuron, BMC Biology, and Frontiers in Cellular Neuroscience. Dr. Paul has received the NARSAD Young Investigator Award (2018), recognizing his promising research in neuroscience. His scientific contributions have been supported by multiple competitive grants from prestigious organizations including the National Institute on Aging (NIA) and the Brain and Behavior Research Foundation. He serves as Principal Investigator on multiple active research projects, including two major grants from the National Institute on Aging focused on cell-type specific risk and resilience in Alzheimer's disease and aging (2021-2024 and 2024-2026), as well as previous projects from the Brain and Behavior Research Foundation investigating Chandelier cells in schizophrenia. His research program demonstrates sustained funding and scientific leadership in the field of interneuron biology and its clinical implications.
Dr Daniel Franchini is a Lecturer in International Law at the School of Law , University of Sheffield. He is also Deputy Director of the Sheffield Centre for International and European Law Research Cluster and Editor in Chief of its Working Papers Series. DPhil and MJur, University of Oxford MA Law, University of Trento (Italy) His research focuses on Public International Law , with specialization in international dispute settlement, state responsibility, jurisdiction and immunities of states, sanctions, and international investment law . His work explores intersections between domestic and international legal frameworks, particularly in cyber conflicts and financial diplomacy. Recent publications highlight his expertise in cyber dispute resolution , state immunity, and sanctions as tools for international conflict management. He has contributed to edited volumes and journals, emphasizing judicial roles in cyber conflicts and the legal implications of economic measures. Dr Franchini has received grants from the Society of Legal Scholars for collaborative research on international dispute settlement. He previously clerked at the Special Tribunal for Lebanon and the International Criminal Tribunal for the former Yugoslavia, and coached Oxford's Jessup International Law Moot Court team.
Elizabeth Bernstein is a Professor of Women's, Gender & Sexuality Studies and Professor of Sociology at Barnard College, Columbia University, where she has been a faculty member since September 2002. Her work bridges sociological theory with feminist analysis, focusing on the intersections of gender, sexuality, and political economy. Bernstein directs significant research initiatives including the Gender Justice and Neoliberal Transformations Working Group, a transnational collaboration among thirteen scholars examining gender justice in contemporary global contexts. She is currently developing a new book project titled "Imagining Immunity: Precarious Bodies and the Governance of Gendered Dis-ease," which explores immunological metaphors in understanding bodily risk and suffering. B.A., University of California, Berkeley M.A., University of California, Berkeley Ph.D., University of California, Berkeley Professor Bernstein's research focuses on the political economy of the body, gender, and sexuality, with particular attention to sexual commerce, sex trafficking, and neoliberal governance. Her work employs ethnographic methods to examine how intimate relations become sites of economic exchange and political regulation. She investigates how concepts of authenticity, freedom, and rights are mobilized in debates about sexual commerce and trafficking. Bernstein's scholarship critically engages with feminist theory, carceral politics, and transnational governance frameworks, challenging conventional approaches to sex work and trafficking that often reinforce punitive systems rather than advancing gender justice. Analysis of Bernstein's scholarly output reveals a consistent trajectory examining the intersections of gender, sexuality, and political economy within neoliberal frameworks. Her work demonstrates increasing attention to transnational governance mechanisms and their impact on intimate relations and bodily autonomy. A notable trend is her critical examination of how anti-trafficking campaigns often employ carceral logic that undermines feminist goals of gender justice. Her scholarship consistently challenges binary frameworks that position sex work solely as exploitation or liberation, instead analyzing the complex economic, political, and social dynamics that shape sexual commerce globally. Bernstein's research has received significant recognition through prestigious awards including: Distinguished Book Award, American Sociological Association, Sociology of Sexualities Section (2020) for "Brokered Subjects" Honorable Mention, Society for the Study of Social Problems Global Division Book Award (2019) Norbert Elias Prize, Norbert Elias Foundation (2009) Distinguished Book Award, American Sociological Association, Sex and Gender Section (2009) Her work has also been supported by major funding organizations including the Institute for Advanced Study, National Science Foundation, Social Science Research Council, AAUW, and Mellon Foundation. As a principal investigator along with Janet Jakobsen for the Gender Justice and Neoliberal Transformations Working Group, Bernstein leads a significant collaborative research initiative sponsored by the Barnard Center for Research on Women. Her grant portfolio demonstrates sustained support from major research institutions, reflecting the significance of her work in gender studies and sociology. While specific student advisees aren't listed in the available materials, her role as a full professor at Barnard College indicates extensive mentorship of undergraduate and likely graduate students in Women's, Gender & Sexuality Studies and Sociology. Bernstein co-leads the Gender Justice and Neoliberal Transformations Working Group, a collaboration among thirteen scholars working transnationally on questions of gender justice. This initiative represents a significant research collective examining how neoliberal policies reshape gender relations globally. Her work with the Barnard Center for Research on Women provides institutional support for this transnational feminist research network, facilitating scholarly exchange and collaborative publication projects that advance critical perspectives on gender, sexuality, and political economy.
Professor Mark Coles serves as Professor of Immunology and Lead for Industrial Strategy and Entrepreneurship at the Kennedy Institute of Rheumatology, University of Oxford, holding concurrent roles as Kennedy Trust Senior Research Fellow, Official Fellow at Reuben College, and Affiliate Faculty at the Wolfson Centre of Mathematical Biology. His interdisciplinary work bridges immunology, computational modeling, and translational research to accelerate therapies for immune-mediated inflammatory diseases. His academic journey began with a BSc in Microbiology from Cornell University (1992), followed by a PhD in Molecular and Cell Biology at UC Berkeley under David Raulet, and postdoctoral training with Dimitris Kioussis at the National Institute of Medical Research. At the University of York (2006-2017), he pioneered stromal immunology research and co-founded the York Computational Immunology Laboratory. Coles' research centers on stromal and systems immunology, with core expertise in stromal cell biology, inflammatory disease mechanisms, and mathematical modeling of immune responses. He champions 3Rs-based approaches (Replacement, Reduction, Refinement) to reduce animal testing through in silico models, integrating spatial single-cell biology with multi-scale computational frameworks to dissect immune function in human tissues. His 2025 publications reveal a cohesive research trajectory applying interdisciplinary methods across diverse disease contexts—from cardiac fibrosis and vaccine responses to arthritis pathogenesis and CAR-T cell therapy—unified by focus on stromal-immune crosstalk and quantitative modeling to identify therapeutic targets. Key honors include: Fellow of the Royal Society of Biology Kennedy Trust Senior Research Fellow As former Director of Graduate Studies (2017-2024) at the Kennedy Institute, Coles mentored numerous graduate students while co-leading major initiatives including the Arthritis Therapy Acceleration Program and Human Cell Atlas medicalization. His entrepreneurial impact spans three co-founded ventures: Simomics Ltd (in silico disease modeling), Lightox Ltd (phototherapy for oral cancer), and Mestag Therapeutics (fibroblast-targeted therapies for cancer/inflammation). He directs the Laboratory of Stromal and Systems Immunology and Oxford Mathematical Immunology Group, fostering collaborations with Christopher Buckley, Calliope Dendrou, and Eamonn Gaffney to develop Quantitative Systems Pharmacology models that translate mechanistic insights into patient therapies.
